These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 28373440

  • 1. Epithelial-Mesenchymal Transition in Non Small-cell Lung Cancer.
    Tsoukalas N, Aravantinou-Fatorou E, Tolia M, Giaginis C, Galanopoulos M, Kiakou M, Kostakis ID, Dana E, Vamvakaris I, Korogiannos A, Tsiambas E, Salemis N, Kyrgias G, Karameris A, Theocharis S.
    Anticancer Res; 2017 Apr; 37(4):1773-1778. PubMed ID: 28373440
    [Abstract] [Full Text] [Related]

  • 2. Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
    Zhou L, Yu L, Wu S, Feng Z, Song W, Gong X.
    World J Surg Oncol; 2015 Aug 01; 13():234. PubMed ID: 26231404
    [Abstract] [Full Text] [Related]

  • 3. Twist may be associated with invasion and metastasis of hypoxic NSCLC cells.
    Wei L, Sun JJ, Cui YC, Jiang SL, Wang XW, Lv LY, Xie L, Song XR.
    Tumour Biol; 2016 Jul 01; 37(7):9979-87. PubMed ID: 26819207
    [Abstract] [Full Text] [Related]

  • 4. Epithelial-mesenchymal Transition (EMT) is Correlated with Patient's Prognosis of Lung Squamous Cell Carcinoma.
    Aruga N, Kijima H, Masuda R, Onozawa H, Yoshizawa T, Tanaka M, Inokuchi S, Iwazaki M.
    Tokai J Exp Clin Med; 2018 Apr 20; 43(1):5-13. PubMed ID: 29637533
    [Abstract] [Full Text] [Related]

  • 5. Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.
    Sung WJ, Park KS, Kwak SG, Hyun DS, Jang JS, Park KK.
    Int J Clin Exp Pathol; 2015 Apr 20; 8(8):8997-9009. PubMed ID: 26464642
    [Abstract] [Full Text] [Related]

  • 6. [Comparison of epithelial-mesenchymal transition-related markers between cancer tissue and tumor emboli].
    He N, Wu GF, Zhao HY, Han HX.
    Zhonghua Bing Li Xue Za Zhi; 2011 Nov 20; 40(11):758-61. PubMed ID: 22336160
    [Abstract] [Full Text] [Related]

  • 7. Krüppel-Like Factor 8 Overexpression Correlates with Poor Prognosis in Non-Small Cell Lung Cancer.
    Li J, Liu Y, Xue J, Xu M, Zhang J, Liu J, Wang W.
    Pathol Oncol Res; 2019 Jan 20; 25(1):115-121. PubMed ID: 28986741
    [Abstract] [Full Text] [Related]

  • 8. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease.
    Mahmood MQ, Ward C, Muller HK, Sohal SS, Walters EH.
    Med Oncol; 2017 Mar 20; 34(3):45. PubMed ID: 28197929
    [Abstract] [Full Text] [Related]

  • 9. Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer.
    Pore M, Meijer C, de Bock GH, Boersma-van Ek W, Terstappen LW, Groen HJ, Timens W, Kruyt FA, Hiltermann TJ.
    Clin Lung Cancer; 2016 Nov 20; 17(6):535-542. PubMed ID: 27363902
    [Abstract] [Full Text] [Related]

  • 10. Correlation of epithelial-mesenchymal transition markers with clinicopathologic parameters in adenocarcinomas and squamous cell carcinoma of the lung.
    Kim SH, Kim JM, Shin MH, Kim CW, Huang SM, Kang DW, Suh KS, Yi ES, Kim KH.
    Histol Histopathol; 2012 May 20; 27(5):581-91. PubMed ID: 22419022
    [Abstract] [Full Text] [Related]

  • 11. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
    Ibrahim R, Matsubara D, Osman W, Morikawa T, Goto A, Morita S, Ishikawa S, Aburatani H, Takai D, Nakajima J, Fukayama M, Niki T, Murakami Y.
    Hum Pathol; 2014 Jul 20; 45(7):1397-405. PubMed ID: 24775604
    [Abstract] [Full Text] [Related]

  • 12. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
    Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O.
    Int J Cancer; 2014 Nov 01; 135(9):2206-14. PubMed ID: 24710653
    [Abstract] [Full Text] [Related]

  • 13. Downregulated vimentin and upregulated E-cadherin in T1 stage non-small-cell lung cancer: does it suggest a mesenchymal-epithelial transition?
    Luo T, Wang L, Wu P, Gong W, Chen W, Zhao H, Zheng Z.
    Neoplasma; 2017 Nov 01; 64(5):693-699. PubMed ID: 28592120
    [Abstract] [Full Text] [Related]

  • 14. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB, Kim YJ, Kim H, Jin Y, Sun PL, Jheon S, Lee JS, Chung JH.
    Ann Surg Oncol; 2013 Dec 01; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [Abstract] [Full Text] [Related]

  • 15. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
    Matsubara T, Toyokawa G, Takada K, Kinoshita F, Kozuma Y, Akamine T, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Mori M.
    PLoS One; 2019 Dec 01; 14(5):e0215103. PubMed ID: 31042721
    [Abstract] [Full Text] [Related]

  • 16. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M, Zhang L, He CS, Hou JH, Lin SX, Hu ZH, Xu F, Zhao HY.
    J Thorac Oncol; 2012 May 01; 7(5):799-807. PubMed ID: 22481233
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma.
    Zhang H, Liu J, Yue D, Gao L, Wang D, Zhang H, Wang C.
    J Clin Pathol; 2013 Nov 01; 66(11):937-45. PubMed ID: 23853314
    [Abstract] [Full Text] [Related]

  • 18. Expression of mesenchymal markers vimentin and fibronectin: the clinical significance in esophageal squamous cell carcinoma.
    Sudo T, Iwaya T, Nishida N, Sawada G, Takahashi Y, Ishibashi M, Shibata K, Fujita H, Shirouzu K, Mori M, Mimori K.
    Ann Surg Oncol; 2013 Dec 01; 20 Suppl 3():S324-35. PubMed ID: 22644514
    [Abstract] [Full Text] [Related]

  • 19. Clinical and Prognostic Significance of the Epithelial-Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score-Matched Analysis.
    Matsubara T, Tagawa T, Takada K, Toyokawa G, Shimokawa M, Kozuma Y, Akamine T, Haro A, Osoegawa A, Mori M.
    Clin Lung Cancer; 2019 Jul 01; 20(4):e504-e513. PubMed ID: 31103348
    [Abstract] [Full Text] [Related]

  • 20. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.
    Wei K, Ye Z, Li Z, Dang Y, Chen X, Huang N, Bao C, Gan T, Yang L, Chen G.
    World J Surg Oncol; 2016 Feb 09; 14(1):34. PubMed ID: 26860827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.